TIGIT and cancer: CD226 and TIGIT are expressed at varying levels depending on the T cell subsets and activation states [10], and imbalance of the CD226/TIGIT signal is involved in the pathogenesis of cancer, autoimmune diseases, and inflammatory responses [9, 11].